Teruhisa Fujii

Last Updated :2022/08/02

Affiliations, Positions
Hiroshima University Hospital, Associate Professor
Web Site
E-mail
teruchanhiroshima-u.ac.jp
Other Contact Details
1-2-3, Kasumi, MInami-ku, Hiroshima city, Japan, Japan
TEL : (+81)082-257-555 FAX : (+81)082-257-558
Self-introduction
After graduating from Hiroshima University, I have worked at Hiroshima University Hospital from 1997. I specialized in Hematology, especially , the field of thrombosis and hemostasis as well asTransfusion Medicine. I am also the head of Hemophilia Treatment center, which was established in Hiroshima University Hospital in 2018.

Basic Information

Major Professional Backgrounds

  • 2007/04/01, 2010/03/31, Division of Blood Transfusion , Hiroshima University Hospital, Assistant profesor, Hiroshima Universty

Educational Backgrounds

  • Hiroshima University, Graduate School, Division of Medicine, Japan, 1994/04, 1997/03
  • Hiroshima University, Faculty of Medicine, Japan, 1984/04, 1991/03

Academic Degrees

  • Doctor of Philosophy in Medical Science, Hiroshima University

Educational Activity

  • [Bachelor Degree Program] School of Medicine : Program of Medicine : Medicine

In Charge of Primary Major Programs

  • Medicine

Research Fields

  • Medicine,dentistry, and pharmacy;Clinical internal medicine;Hematology

Research Keywords

  • guidline
  • hemophilia
  • transfusion
  • inhibitor
  • HIV
  • CD4
  • aging

Affiliated Academic Societies

  • The Japanese Society of Hematology, 1993/05
  • The Japanese Society of Transfusion Medicine and cell therapy, 2001/01
  • The Japanese Society for AIDS Research
  • The Japanese Society on Thrombosis and Hemostasis
  • The Japanese Association for Infectious Disease
  • International Society on Thrombosis and Hemostasis, 2011/06
  • World Federation of Hemophilia, 2008/03
  • The Japanese Society of Internal Medicine
  • The Japanese Society for Laboratory Hematology, 2015/07

Educational Activity

Course in Charge

  1. 2022, Undergraduate Education, Year, Clinical diagnosis and treatment II
  2. 2022, Undergraduate Education, Year, Systemic Disease Control
  3. 2022, Undergraduate Education, Intensive, Practice of Medicine I
  4. 2022, Undergraduate Education, Intensive, Practice of Medicine II
  5. 2022, Undergraduate Education, First Semester, Special Subject

Research Activities

Academic Papers

  1. Inter-observer reliability of three different radiographic scores for adult haemophilia, HAEMOPHILIA, 17(1), 134-138, JAN 2011
  2. A case of HIV encephalitis with subacute progressive memory and gait disturbance, Journal of Japan society of internal medicine, 84, 120-121, 19950401
  3. Plasma cells composing plasmacytoma have phenotypes different from those of myelowa cells, American Journal of Hematology, 53, 251-253, 19960401
  4. Evaluation of the change of bleeding episodes in hemophiliac patients with HIV infectiou after medication of protease inhibitors., AIDS Research Newsletter, 11, 34, 19970401
  5. Change in viral DNA and mRNA burdens in peripheral blood mononuclear cells in a patients with HIV-1 after stopping anti-retroviral treatment., Journal of AIDS Research, 4(3), 104-107, 20020401
  6. Plasma cells composing plasmacytoma have phemotype different from those of myeloma cells, Am. J. Hematol. =, 53, 251-253, 19960401
  7. A point mutation in gycoprotein IX coding sequence causes impared surface expression of GP Ib/IX/V complex in two families with Bernard-Soulier syndrome, Thoromb Haemost, 76, 874-878, 19960401
  8. Oligoclonal accumulation of T cells in peripheral blood from patients with idiopathic thrombocytopenic purpura, Brit. J. Haematol.=, 95, 732-737, 19960401
  9. Potential interaction between ritonavir and carbamazepine, PHARMACOTHERAPY, 20, 851-854, 20000401
  10. Change in plasma viral load, and viral DNA and mRNA burdens, in peripheral blood mononuclear cells from patients infected with HIV-1, J. Infection, 42(1), 20-26, 20010401
  11. A point mutation Glycoprotein IX coding sequence(Cys73(TGT) to Tyr (TAT)) causes impaired surface expression of GPIb/IX/V complex in two families with Bernard-Soulier Syndrome., Thrombosis and Haemostasis, 76, 874-878, 19960401
  12. Usefulness of Improved Measurement of Platelet RNA Stained with Thizole Orange (T.O); High Percentage of T.O. Positive Platelet is Distinctive Feature of ITP when Compared with Chronic Thrombocytopenia Caused by Other Disorders., 38th Annual Meeting of the American Society of Hematology December 6-10(7) = Orlando= Florida, 88 2/2, supplement 59b, 19960401
  13. The change of HIV-1 proviral DNA copy number in peripheral blood mononuclear cells during anti-HIV therapies, 12th World AIDS Conference, 19980401
  14. CD4 Viral Load Discrepancy, J. AIDS Research, 54(10), 837-841, 20010401
  15. ★, Management of haemostasis during hemodialysis in a patient with haemophilia B, HAEMOPHILIA, 14(5), 1135-1137, 20080101
  16. ★, A new approach to detect reticulated platelets stained with Thiazole Orange in thrombocytopenic patients, THROMBOSIS RESEARCH, 97(6), 431-440, MAR 15 2000
  17. Disseminated mucormycosis in an acquired immunodeficiency syndrome (AIDS) patient, INTERNAL MEDICINE, 42(1), 129-130, JAN 2003
  18. HLA-B polymorphism in Japanese HIV-1-infected long-term surviving hemophiliacs, VIRAL IMMUNOLOGY, 18(3), 500-505, FAL 2005
  19. Abacavir/Lamivudine versus Tenofovir/Emtricitabine with Atazanavir/Ritonavir for Treatment-naive Japanese Patients with HIV-1 Infection: A Randomized Multicenter Trial, INTERNAL MEDICINE, 52(7), 735-744, 2013
  20. ★, Switching Tenofovir/Emtricitabine plus Lopinavir/r to Raltegravir plus Darunavir/r in Patients with Suppressed Viral Load Did Not Result in Improvement of Renal Function but Could Sustain Viral Suppression: A Randomized Multicenter Trial, PLOS ONE, 8(8), AUG 8 2013
  21. A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics, HAEMOPHILIA, 19(6), 853-860, NOV 2013
  22. Postsurgical coagulopathy in a hemophilia A patient with inhibitors: efficacy of recombinant factor VIIa, JOURNAL OF ANESTHESIA, 28(4), 621-624, AUG 2014
  23. Plasma concentration of cartilage oligomeric matrix protein(COMP) in hemophilic patients., HAEMOPHILIA, 14(supl), 22-22, 2008
  24. THE JAPANESE GUIDELINE FOR THE HEMOSTATIC THERAPY OF PATIENTS WITH CONGENITAL HEMOPHILIA AND INHIBITORS , J Thrombosis and Haemostasis, 7(supple2), 526-526, 2009
  25. Inter-observer reliability of three different radiographic evaluation systems for haemophilic arthropathy, Haemophilia, 16(suppl4), 26-26, 2010
  26. Relationship between haemarthrosis and haemophilic arthropathy, Haemophilia, 16(suppl4), 27-27, 2010
  27. Long-term clinical safety of FEIBA, activated prothrombin complex concentrate (APCC) in Japanese inhibitor subjects: an update of postauthorization safety surveillance (PASS) program, Haemophilia, 16(suppl4), 31-31, 2010
  28. Hemostatic management for intractable trraumatic hemorrhage using fibrinogen concentrates and recombinant actvated factor VII, THE JAPANESE JOURNAL OF CLINICAL HEMATOLOGY, 55(2), 234-237, 2014
  29. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A, J Thrombosis and Haemostasis, 13, 9-10
  30. ★, A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors., Haemophilia, 1-8
  31. Three older adults with full-blown AIDS diagnosed only after pre-transfusion viral marker screening tests, J AIDS Research, 18(3), 224-229
  32. Efficacy of secondary prophylaxis on annual bleeding ratio (ABR) in adult patients with hemophilia:a single center observation study in Japan., J Thrombosis and Haemostasis, 13(suppl), 346-346, 201506
  33. Barriers to inform hemophilic carriers of that possibility in Japan, J Thrombosis and Haemostasis, 13(suppl), 399, 201506
  34. A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors, HAEMOPHILIA, 23(1), 59-66, JAN 2017
  35. Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product, INTERNATIONAL JOURNAL OF HEMATOLOGY, 105(3), 280-286, MAR 2017
  36. Three older adults with full-blown AIDS diagnosed only after pre-transfusion viral marker screening tests, Journal of AIDS Research, 18(3), 224-229
  37. The bone metabolism abnormality of HIV infected patients and the factor influenced it an analysis in Hiroshima University Hospital, Journal of AIDS research, 19(1), 32-36
  38. Exited half life product for hemophilia, Japanese Journal of Thrombosis and Hemostasis, 28(4), 472-479
  39. Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations, INTERNATIONAL JOURNAL OF HEMATOLOGY, 106(5), 704-710, NOV 2017
  40. Anti-human neutrophil antigen-1a,-1b, and-2 antibodies in neonates and children with immune neutropenias analyzed by extracted granulocyte antigen immunofluorescence assay, TRANSFUSION, 57(11), 2586-2594, NOV 2017
  41. A case report on the successful perioperative management of hepatectomy for hepatocellular carcinoma in a patient with von Willebrand disease, INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS, 44, 131-134, 2018
  42. A Single Center Study of the Treatment Outcome of HCV and the Long-term Prognosis in Patients with HIV/HCV-Coinfection, The journal of the Japanese Association for Infectious Diseases, 91(6), 924-929
  43. ★, Ischaemic events are rare, and the prevalence of hypertension is not high in Japanese adults with haemophilia: First multicentre study in Asia, HAEMOPHILIA, 25(4), E223-E230, 201907
  44. Mothers' intentions and behaviours regarding providing risk communication to their daughters about their possibility of being haemophilia carriers: A qualitative study, HAEMOPHILIA, 25(6), 1059-1065, 201911
  45. Oral environment and taste function of Japanese HIV-infected patients treated with antiretroviral therapy, AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 32(7), 829-834, 20200702
  46. Brief HIV stigma scale for Japanese people living with HIV: validation and restructuring using questionnaire survey data., AIDS CARE, 28(1), 1-9
  47. Clinical Outcomes of Post-exposure Prophylaxis following Occupational Exposure to Human Immunodeficiency Virus at Dental Departments of Hiroshima University Hospital, CURRENT HIV RESEARCH, 18(6), 475-479, 2020
  48. Brief HIV stigma scale for Japanese people living with HIV: validation and restructuring using questionnaire survey data, AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 32, 1-9, 20201209
  49. Budget impact analysis of Jivi (damoctocog alfa pegol, Bay 94-9027) in severe hemophilia A in Japan, JOURNAL OF MEDICAL ECONOMICS, 24(1), 218-225, 20210101
  50. Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis, HEMATOLOGY, 26(1), 186-198, 20210101
  51. ★, Long-term impact of haemarthrosis on arthropathy and activities of daily living in Japanese persons with haemophilia, Haemophilia, 26(3), 124-127, 20200615
  52. ★, Weather changes leading to bleeding in arthropathic joints among individuals with haemophilia: symptoms of meteoropathy?, Haemophilia, 26(6), 346-248, 20201103

Invited Lecture, Oral Presentation, Poster Presentation

  1. The Parameters of Modified Clot Waveform Analysis Using the Plasmas of Hemophilia A Patients Treated with Emicizumab, N. Yamasaki, T.Fujii, K. Kajihara, H. Nakagawa, M. Yokozaki, XXVIII Congress of the International Society on Thromobosis and Haemostasis, 2020/07, Without Invitation, English, International Society of Thrombosis & Haemostasis, Milan, other
  2. BUDGET IMPACT ANALYSIS OF BAY-94 9027 (DAMOCTOCOG ALFA PEGOL) IN SEVERE HEMOPHILIA A (HA) IN JAPAN, Teruhisa Fujii, Yuko Kidoguchi, Noriko Takahashi, Eric Yu, Dilinuer Ainiwaer, Aidan Byrne, 2020/10, Without Invitation, English, Japan society of Hematology, kyoto, other
  3. Plasma factor VIII activity measured by coagulation one-stage and chromogenic assays in patients with hemophilia A treated with emicizumab, T.Fujii,, T.Fujii, N. Yamasaki,T. Inoue, XXVIII Congress of the International Society on Thromobosis and Haemostasis, 2020/07, Without Invitation, English, International Society of thrombosis & haemostasis, Milan, other
  4. Comparison of mindset between the medical doctors and the staffs of genetic counseling about support of hemophilia carriers in Japan, Tomie Fujii, Teruhisa Fujii, Yukiko MIYAKOSHI, XXVII Congress of the International Society on Thromobosis and Haemostasis, 2019/07/09, Without Invitation, English
  5. Extended half-life factor VIII management of hemophilia A undergoing surgery is not only efficient but also contributes to saving the factor consumption compared to standard half-life products., T.FUJII,T.Fujii, N. Yamasaki, XXVII Congress of the International Society on Thromobosis and Haemostasis, 2019/07/08, Without Invitation, English, nternational society of thrombosis & haemostasis, Melborne
  6. Psychosocial factors influencing continuation of medical attendance among Japanese HIV patients., Fumiko Kagiura, Fujii, T., Takayama, T, Jyozaki, M, Shimoji, Y., Kakehashi, M., The 4th International Association for the Social Sciences and Humanities in HIV Conference, 2018/07, Without Invitation, English, other
  7. Efficacy and safety of bolus infusions of rFVIII-Fc during the perioperative bleedings in two patients with hemophilia A., Naoya Yamasaki, Teruhisa Fujii, the 40th Congress of the Japanese Society on Thrombosis and Hemostasis, 2018/06, Without Invitation, English, APSTH, Sapporo, other
  8. The mothers’ thought and measures for the hemophilic carriers to notify their daughters in Japan, Tomie Fujii, Teruhisa Fujii, Sanae ORIYAMA, Yukiko MIYAKOSHI, XXXIII International Congress of the World Federation of Hemophilia, 2018/05, Without Invitation, English, World Federation of Hemophilia, Glasgow, UK
  9. Individualized prophylaxis can contribute to decreasing annualized bleeding ratio(ABR) in adult persons with hemophilia A, Teruhisa Fujii Naoya Yamasaki, Seiji Saito, Tomie Fujii, XXXIII International Congress of the World Federation of Hemophilia, 2018/05, Without Invitation, English, World Federation of Hemophilia, Glasgow, UK.
  10. Correlation between factor VIII or IX activity and APTT in patients with hemophilia patients, Naoya Yamasaki,Seiji Saito,Teruhisa Fujii, East Asia Hemophilia Forum, 2017/10, Without Invitation, English, Taichyun
  11. Is the result of Clot Waveform Analysis (CWA) different in hemophilia A and B?, Naoya Yamasaki, Teruhisa Fujii, The 79th congress Japanese society of hematology, 2017/10, Without Invitation, Japanese, other
  12. Should hemostatic ability of hemophilic patients be evaluated based on coagulation factor activity?, Naoya Yamasaki, Teruhisa Fujii, East Asia Hemophilia Forum, 2017/10, Without Invitation, English, other
  13. Can tertiary prophylaxis gring about zero bleeding in adult persons with hemophilia?, Teruhisa Fujii, Naoya Yamasaki, Seiji Saito,T Fujii, XXVI Congress of the International Society on Thromobosis and Haemostasis, 2017/07, Without Invitation, English, International society on thrombosis and hemostasis, Berlin, Germany, other
  14. Activated partial thromboplastin time (APTT) of persons with haemophilia A can serve as a surrogate marker of their factor VIII activity, Teruhisa Fujii, Naoya Yamasaki, Seiji Saito,T Fujii, XXXII International Congress of the World Federation of Hemophilia, 2016/07, Without Invitation, English, World Federation of Haemophilia, Orlando, Frorida
  15. Advocatiing scoring system to evaluate risk of intracranial hemorrhages in adult hemophilia, Seiji.Saito,, Naoya Yamasaki, Teruhisa.Fujii, 2016, Without Invitation, Japanese
  16. Influence of quantity of von Willebrand factor antigen in hemophilia A, Naoya Yamasaki, Seiji Saito, Teruhisa Fujii, 2016, Without Invitation, Japanese
  17. Sub-analysis of Japanese patietents with hemophilia B in rIX-FP clinical trial, Mitsuhiro Kuwabara, Hideji Hanabusa, Katsuyuki Fukutake, Kagehiro Amano, Masashi Taki, Jisin Yang, Midori Kobayashi, Koji Yamamoto, Tadashi Matsushita, Midori Shima, Keiji Nogami, Teruhisa Fujii, Satoshi Higasa, Michio Sakai, 2016, Without Invitation, Japanese
  18. The current status of prophylaxis in adult patients with hemophilia: an institution observation study, Seji Saito,Naoya Yamasaki,Teruhisa Fujii,Tatsuo Ichinohe, 2015/10, Without Invitation, English
  19. Correlation between factor VIII activity and APTT in patients with hemophilia A, Naoya Yamasaki,Seiji Saito,Teruhisa Fujii, 2015/10, Without Invitation, English
  20. Efficacy of secondary prophylaxis and consideration of the factors in adult patients with hemophilia, 2015/10, Without Invitation, Japanese
  21. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A, Lalezari S, Fujii T, Kwong YL, Delesen H, Shah A,Tu€ckmantel C, van Heerde W and Enriquez MM, XXV Congress of the International Society on Thromobosis and Haemostasis, 2015/06, Without Invitation, English
  22. Efficacy of secondary prophylaxis on annual bleeding ratio (ABR) in adult patients with hemophilia:a single center observation study in Japan. , 2015/06, Without Invitation, English
  23. Barriers to inform hemophilic carriers of that possibility in Japan, Fujii T, Murakami A, Fujii T and Miyakoshi Y, XXV Congress of the International Society on Thromobosis and Haemostasis, 2015/05, Without Invitation, English
  24. Influence of wether on joint bleedings and hemorrage reduction effect by prophylaxis in hemophilia, 2014/10, Without Invitation
  25. Does bad weather have a bad influence on joint bleedings in patients with haemophilic arthropathy?, 2014/05, Without Invitation
  26. “Moba-Roku”: use of a mobile recording system for tracking treatment infusions, 2014/05, Without Invitation
  27. The relationship with weather and joint bleedings in haemophilic patients. , 2013
  28. Dissimilarity of daily lives and joint damage between young and middle aged people with haemphlia in Japan., 2012
  29. Plasma concentration of cartilage oligomeric matrix protein(COMP) in hemophilic patients., 2008
  30. Current situation and prevention of HIV/AIDS, 2007
  31. Change in plasma viral load, and viral DNA and mRNA burdens in peripheral blood mononuclear cells from patients infected with HIV-1., 2001
  32. Is human imunodeficiency virus -1 mRNA burdens in peripheral blood mononuclear cells (PBMCs) possible to be anew clinical marker in HIV-1 infected patients?, 1999
  33. The change of HIV-1 RNA copy number in peripheral blood monouclear cells during anti-HIV therapies, 1998
  34. Usefulness of improved measurement of platelet RNA stained with Thiazole Orange: High percentage of TO positive platelets is distinctive feature of ITP, 1997
  35. Evaluation pf thrombopoiesis by the measurement of immature platelets with thiazole orange and serum thrombopoietin concentration in thrombocytopenic disorders, 1997
  36. Usefulness of platelet RNA measurement for the analysis of platelet productive activity and differential diagnosis in various thrombocytopenia, 1996
  37. Usefulness of improved measurement of TO positve platelets is distinctive feature of ITP when compared with chronic thrombocytopenia caused by other disorders, 1996
  38. Chromogeric assay may be more superior to one-stage assay for measuring factor VIII activity?, Naoya Yamasaki,, Kyoko Kajihara, Hiromi Nakagawa, Michiya Yokozaki, Terhisa Fujii, The 79th annual conference of Japan Society of Hematology, Without Invitation, Japanese, Japan Society of Hematology, Osaka, other

Social Activities

History as Committee Members

  1. a director, 2014, The Japanese Society of Transfusion and Cell Therapy

Organizing Academic Conferences, etc.

  1. Chairman, 2014/10, 2014/10
  2. JSTH scientific standardization committee symposium 2019, The chief of hemophilia sub-committee, scientific standardization committee, JSTH, 2019/02, 2019/02

History as Peer Reviews of Academic Papers

  1. 2020, Journal of Blood Medicine, Editor, Editor
  2. 2020, International Journal of Hematology, Others, reviewer, 3
  3. 2015, Journal of Internal medicine, Others, Peer Reviewer, 2
  4. 2015, International Journal of Hematology, Others, Peer Reviewer, 2
  5. 2015, Haemophilia, Others, Peer Reviewer, 2
  6. 2015, Japanese Journal of Transfusion and Cell Therapy, Others, Peer Reviewer, 1
  7. 2015, Journal of Bone and Mineral Metabolism, Others, Peer Reviewer, 1
  8. 2015, The Japanese Journal of Thrombosis and Hemostasis, Others, Peer Reviewer, 1
  9. 2016, International Journal of hematology, Others, peer reviewer, 3
  10. 2016, Journal of Internal Medicine, Others, peer reviewer, 5
  11. 2017, International journal of hematology, Others, 3
  12. 2017, Internal medicine, Others
  13. 2018, International journal of hematology, Others, Peer Reviewers, 2
  14. 2018, Journal of Blood Transfusion Medicine, Editor, 1
  15. 2018, Trombosis Research, Others, Peer Reviewer, 1